FLT3 is also highly expressed in KMT2Ar acute lymphoblastic leukemia (ALL), a disease that has been shown to undergo lymphoid-to-myeloid lineage switch following CD19-CAR-T cell therapy as a mechanism of antigen escape.118. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.